Apogee Therapeutics Inc.

NASDAQ: APGE · Real-Time Price · USD
37.42
-0.70 (-1.84%)
At close: Aug 15, 2025, 2:57 PM

Apogee Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022
Revenue
n/a n/a n/a
Cost of Revenue
189K n/a n/a
Gross Profit
-189K n/a n/a
Operating Income
-216.87M -93M -30.73M
Interest Income
34.74M 9.02M 92K
Pretax Income
-182.13M -83.98M -39.78M
Net Income
-182.15M -83.98M -39.78M
Selling & General & Admin
49.01M 24.58M 2.94M
Research & Development
167.87M 68.42M 27.79M
Other Expenses
n/a n/a n/a
Operating Expenses
216.87M 93M 30.73M
Interest Expense
n/a n/a 9.15M
Selling & Marketing Expenses
n/a n/a n/a
Cost & Expenses
216.87M 93M 30.73M
Income Tax Expense
-18K n/a -33.52K
Shares Outstanding (Basic)
55.19M 50.66M 50.67M
Shares Outstanding (Diluted)
55.19M 50.66M 50.67M
EPS (Basic)
-3.3 -1.66 -0.79
EPS (Diluted)
-3.3 -1.66 -0.79
EBITDA
-216.87M -83.98M -39.78M
EBIT
-182.13M -83.98M -39.78M
Depreciation & Amortization
189K 9.02M n/a